Next Article in Journal / Special Issue
Fe, Zn and Se Bioavailability in Chicken Meat Emulsions Enriched with Minerals, Hydroxytyrosol and Extra Virgin Olive Oil as Measured by Caco-2 Cell Model
Previous Article in Journal
Olive Oil Consumption and Bone Microarchitecture in Spanish Women
Previous Article in Special Issue
Association between Dietary Zinc Intake and Hyperuricemia among Adults in the United States
Open AccessArticle

Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls

Department of Neurology, Otto-von-Guericke-University, 39120 Magdeburg, Germany
Institute of Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke-University, 39120 Magdeburg, Germany
Department for Biometrics and Medical Informatics, Otto-von-Guericke-University, 39120 Magdeburg, Germany
Institute of Molecular and Clinical Immunology, Otto-von-Guericke-University, 39120 Magdeburg, Germany
Author to whom correspondence should be addressed.
Nutrients 2018, 10(8), 967;
Received: 30 June 2018 / Revised: 22 July 2018 / Accepted: 24 July 2018 / Published: 26 July 2018
(This article belongs to the Special Issue Health Effects of Dietary Zinc)
Objective: Diminished blood levels of zinc have been reported to be associated with T-cell-mediated autoimmunity, which has been implicated in multiple sclerosis (MS). We aimed to compare the distribution of serum zinc status in MS patients with that in healthy controls (HCs) and to investigate a potential correlation with clinical state, through analysis of serum zinc concentration in MS patients suffering from different disease subtypes. Methods: Serum zinc concentrations of 133 patients with relapsing (RMS) and 18 patients with the progressive form of MS (PMS), according to the McDonald criteria of 2010, were measured. Clinical status was quantified using the Expanded Disability Status Scale (EDSS). Zinc concentrations were also determined in the sera of 50 HCs, matched for age and sex at a group level. Results: MS patients showed significantly lower zinc concentrations (mean (SD)) than HCs (12.5 (2.1) µmol/L vs. 14.6 (2.3) µmol/L, p < 0.001). In contrast, we did not find any difference between RMS (12.4 (2.0) µmol/L) and PMS (13.0 (3.0) µmol/L) cases (p = 0.8). Patients receiving disease-modifying treatment showed lower mean (SD) serum zinc levels than untreated cases (12.3 (1.9) µmol/L vs. 13.5 (3.2) µmol/L, p < 0.03). Zinc levels were not related to disease duration, EDSS, annual relapse rate, or the median number of relapses. Conclusions: The data suggest that a diagnosis of MS is related to lower serum zinc concentrations than in HCs, and concentrations were lower still under disease-modifying therapy. However, zinc levels did not predict disease subtypes or disability status. View Full-Text
Keywords: multiple sclerosis; zinc; disease-modifying drugs multiple sclerosis; zinc; disease-modifying drugs
Show Figures

Figure 1

MDPI and ACS Style

Pawlitzki, M.; Uebelhör, J.; Sweeney-Reed, C.M.; Stephanik, H.; Hoffmann, J.; Lux, A.; Reinhold, D. Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls. Nutrients 2018, 10, 967.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop